CIMA LABS INC. has signed a second agreement with Schwarz Pharma for a controlled release formulation of its DuraSolv dosage form of an undisclosed prescription product. The Agreement is expected to add approximately $ 1.3 million in product development fees and licensing revenue during the product development phase, which is estimated at two years. “This Read more about Cima And Schwarz Sign Development And Supply Agreement[…]
Gone are the days when a great physique was a characteristic feature of people serving in the armed forces or sports persons or athletes. The modern world in a health conscious world where a physically fit body is considered to be one of the most valuable assets that a human being can possess or is Read more about Synthobolic Extreme Synthol – Guaranteed Size and Muscle Definition[…]
Generex Biotechnology Corporation and Presspart Group Limited have entered into a commercial supply agreement for a key component of Generex’s RapidMist device. Under the agreement, Generex will purchase its requirements of pharmaceutical aerosol cans used for the buccal delivery of insulin from UK-based Presspart. Presspart has granted an exclusive license to Generex for the use Read more about Generex Receives License From Presspart[…]
Antares Pharma, Inc. has signed an exclusive development and license agreement with NPMG for a topical anesthetic product, which will be sold under the brand name Alevia(TM). The product will be based on Antares Pharma’s proprietary ATD(TM) gel technology, and will contain lidocaine and tetracaine at low levels to allow distribution and use without a Read more about Antares Pharma NPMG Alliance For Topical Anesthetic[…]
SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]
Boston Life Sciences, Inc. has announced it has entered into an agreement with Codman & Shurtleff, Inc., a Johnson & Johnson subsidiary, related to BLSI’s development of Inosine for stroke. Under the agreement, Codman will supply BLSI with implantable pumps and catheters for BLSI’s preclinical and clinical studies for Inosine, and in exchange, Codman will Read more about Drug Delivery Device Supply Agreement For Boston Life Sciences And Codman & Shurtleff[…]
Skyepharma has initiated Phase III clinical trials of the oral controlled release formulation of GlaxoSmithKline‘s Requip (Ropinirole HCl). The new once daily formulation for Parkinson’s disease has been developed utilizing SkyePharma’s Geomatrix technology. Requip OCR is expected to simplify the treatment regime for patients using this drug, thus improving patient convenience and compliance. The company Read more about Skyepharma Begins Requip Ocr Clinical[…]
Laureate Pharma L.P. and Southern Research Institute have initiated a strategic collaboration agreement related to developing and manufacturing drug-delivery products using Southern Research’s proprietary microencapsulation process technologies. Under the agreement, Laureate Pharma and Southern Research will collaborate to provide pharmaceutical clients with full microencapsulation services that range from development through commercial scale manufacturing. Terms of Read more about Laureate And Southern Research Institute Announce Collaboration[…]
Discovery Laboratories, Inc. and Aerogen, Inc. have entered into a collaborative relationship to evaluate the use of Discovery’s proprietary humanized lung surfactant with Aerogen’s Aeroneb Professional Nebulizer System (Aeroneb Pro), for the delivery of aerosolized surfactants to prevent and treat respiratory disease in the hospital. Aerogen’s commercially available Aeroneb Pro is a new nebulizer designed Read more about Discovery And Aerogen Collaborate[…]
Berna Biotech Ltd. and Iomai Corporation have announced a collaboration for the development of vaccines for administration using a skin patch. The collaboration will pool Berna’s expertise in the development of vaccines and novel adjuvants with Iomai’s expertise in skin delivery using its proprietary patch technology. Needle-free delivery has become a global priority because of Read more about Berna And Iomai Announce Collaboration[…]